Pharmaceutical Industry Financial Analysis
description
Transcript of Pharmaceutical Industry Financial Analysis
![Page 1: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/1.jpg)
Pharmaceutical Industry Financial AnalysisFE 449: Corporate Finance
James PottsRichard SuHin MokEmily Wu
![Page 2: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/2.jpg)
Industry Highlights
2009 Industry Sales: $300.3B Brand Name vs. Generics
◦PatentsHigh Fixed Costs
◦Lengthy Drug Development CycleConsolidation by M&A
◦Bio-tech
![Page 3: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/3.jpg)
Research & DevelopmentThe pharmaceutical
industry is the most research-intensive in the US.
FY2009: Over $65.3 Billion invested in R&D
Constantly striving to produce more drugs
Est. $1B spent in R&D per drug under development.
R&D Expenditures (in billions)
Pfizer $7.85
AstraZeneca $4.41
Eii Lilly $4.33
Bistol-Myers $3.65
![Page 4: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/4.jpg)
Consolidation and M&ABig pharmaceuticals
look to diversify products as well as gain valuable IP rights, expertise, capacity, etc
Biotech and big pharmaceuticals have driven M&A over the past year
Alliances to overcome economy, innovate
Recent notable M&A’s:◦Wyeth > Pfizer,
$64B◦Schering-
Plough > Merck, $47B
◦Genentech > Roche Holdings, $44B
![Page 5: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/5.jpg)
Firm Valuation OverviewEli Lilly• Market Cap: $37.88
AstraZeneca• Market Cap: $67.8B
Bristol-Myers Squibb• Market Cap: $43.75B
Pfizer• Market Cap: $133.78B
![Page 6: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/6.jpg)
Eli Lilly Based in IndianaHistory of success with anti-
depressants Notable Former Board Members
◦ George H.W. Bush◦ Kenneth Lay
Eli Lilly
Valuation Summary
Value per share
Comparable Company Mulptiles EBITDA Valuation 49.02$
Comparable Company Mulptiles Net Income Valuation 38.50$
DCF Analysis Valuation (0% growth in long run) 41.62$
Comparable Target Valuation 39.24$
Mean 42.10$
![Page 7: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/7.jpg)
DCF: Growth vs. Discount Rate
Eli LillyShare Price with various perpetual growth and discount rates
Growth Rate-1.0% -0.5% 0.0% 0.5% 1.0% 1.5% 2.0% 2.5% 3.0%
6.00% $51.34 $55.30 $59.92 $65.38 $71.93 $79.94 $89.95 $102.82 $119.987.00% $42.42 $45.28 $48.56 $52.34 $56.74 $61.95 $68.21 $75.85 $85.407.79% $36.79 $39.06 $41.62 $44.54 $47.88 $51.76 $56.30 $61.70 $68.228.00% $35.50 $37.65 $40.06 $42.80 $45.92 $49.53 $53.74 $58.71 $64.689.00% $29.99 $31.64 $33.48 $35.53 $37.83 $40.44 $43.43 $46.87 $50.89
10.00% $25.50 $26.80 $28.23 $29.80 $31.55 $33.51 $35.71 $38.21 $41.0611.00% $21.78 $22.81 $23.95 $25.18 $26.55 $28.05 $29.73 $31.60 $33.7012.00% $18.64 $19.48 $20.39 $21.38 $22.46 $23.65 $24.95 $26.39 $27.99
Discount Rate
![Page 8: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/8.jpg)
Eli Lilly Eli LillyProduct Portfolio Sales Breakdown
ProductPatent
Expiration Year
2009 Total%Δ from
2008
Percent of Total
RevenueDrug Category
Zyprexa 2011 4,915.7$ 5% 23% Neuroscience Cymbalta 2012 3,074.7 14% 14% Neuroscience Humalog 2012 1,959.0 13% 9% EndocrinologyAlmita 2016 1,706.0 48% 8% OncologyCialis 2017 1,559.1 8% 7% CardiovascularGemzar 2010 1,363.2 -21% 6% OncologyAnimal Health Products - 1,207.2 10% 6% -Evista (+) Multiple 1,030.4 -4% 5% EndocrinologyHumulin - 1,022.0 -4% 5% EndocrinologyForteo - 816.7 5% 4% EndocrinologyStrattera 2016 609.4 5% 3% NeuroscienceOther 1,908.1 1% 9% -
Net Product Sales 21,171.5 6% 97%Collaboration and other Revenue 664.5 49% 3%
Total Revenue 21,836.0 7% 100%
(+) Patents for the treament and and prevention of osteoperosis extend expire in 2012 and 2014. Patents for its dosage form expire in 2017.
Total Revenue
![Page 9: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/9.jpg)
AstraZeneca (NYSE: AZN) Incorporated in
1992, based in the UK
Focused on the discovery, development, and commercialization of prepared medicines.
7th largest pharmaceutical company based off revenues
Operated in over 100 countries
Company Snapshot
Ticker NYS: AZN
Closing Price (As of 11/26/2010) $48.01
Market Cap ( As of 11/26/2010) $67.82 B
Revenue $33.60 B
![Page 10: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/10.jpg)
AstraZeneca Major ProductsFocused in 6 areas of healthcare10 drugs each over $1B in revenues
annually in 200960 major R&D collaborations last three
years
![Page 11: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/11.jpg)
AstraZeneca ValuationCompared with Pfizer, Abbott, Roche,
Novartis, GlaxoSmithKlineEBITDA
◦ Represents profit of business when only considering operations
◦ Good way to predict growth of business
AstraZeneca price
BEV/EBITDA $81.80
BEV/REV $60.52
MEDIAN $71.16
![Page 12: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/12.jpg)
Bristol MyersHeadquartered in
New York City11 Key drugs,
◦ Plavix7 drugs in phase III
as of 2009Focused on
◦ Cancer◦ HIV/AIDS◦ Cardiovascular◦ diabetes
Key Financials
Revenue $18B
Net Income $10B
EPS $5.35
Market Cap $43B
ROA 35%
![Page 13: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/13.jpg)
Bristol MyersCompared with: Pfizer, Gilead,
Baxter, Eli Lilly, and Amgen◦BEV/REV = $25.38◦ BEV/EBITDA = $25.28◦Price/Sales = $24.79
Plavix exclusive loss in US in 2011 and in Canada in 2012
Avapro exclusive loss in US 2012 and in Europe in 2013
![Page 14: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/14.jpg)
Pfizer, Inc. (NYSE: PFE)The largest prescription drug manufacturer
worldwideHolds a diversified arm that also
manufactures drugs for animals, as well as gelatin capsules
Notable products: Lipitor, Viagra, Celebrex
![Page 15: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/15.jpg)
Notable EventsPfizer acquired Wyeth in 2009 for
over $64 B.Beneficial through legacy
products, expertise, capacity, savings on R&D.
Result: on pace to grow in FY2010 over 50% versus FY2009 (3.55%)
![Page 16: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/16.jpg)
Pfizer ValuationCompCo:
◦ BEV/EBITDA: $23.18◦ BEV/REV: $21.74
CompM&A:◦ BEV/EBITDA: $27.97◦ BEV/REV: $21.86
DCF: $44.54◦ High due to unpredictability of
extraordinary items, Wyeth legacy products
Blended Price: $26.34
![Page 17: Pharmaceutical Industry Financial Analysis](https://reader033.fdocuments.net/reader033/viewer/2022061116/546614e7af795982288b71e5/html5/thumbnails/17.jpg)
Thanks for your time!Questions?
◦Comments?